Loading organizations...
§ Private Profile · Pleasanton, CA, USA
A CRO providing translational sciences, clinical pharmacology, and bioanalysis to support biopharmaceutical drug development.
Based in Pleasanton, California, Amador Bioscience is a contract research organization providing translational sciences, quantitative clinical pharmacology, and regulatory filing services to biopharmaceutical companies. The enterprise operates on a fee-for-service business model to support novel therapeutic drug development from preclinical research stages through final market approval. Amador Bioscience has raised over $100 million in total funding, supported by a syndicate of institutional investors that includes Sequoia Capital China, GL Ventures, and MSA Capital. The organization generates approximately $16.8 million in revenue and expanded its technical capabilities by acquiring the Ann Arbor Pharmacometrics Group in late 2021. Operating with a workforce of over 400 employees, the firm recently opened a new GxP facility in Germantown, Maryland, to scale its clinical trial operations. Amador Bioscience was founded in 2018 by pharmaceutical industry veterans Bing Wang and Xiaomin Chen.
Amador Bioscience has raised $60.0M across 1 funding round.
Amador Bioscience has raised $60.0M in total across 1 funding round.
Amador Bioscience has raised $60.0M across 1 funding round. Most recently, it raised $60.0M Series B in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 30, 2021 | $60M Series B | Jenny Zeng | Co WIN Ventures, Sequoia Capital | Announced |
Amador Bioscience has raised $60.0M in total across 1 funding round.
Amador Bioscience's investors include Jenny Zeng, Co-win Ventures, Sequoia Capital.